Percutaneous Clot Removal Devices in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Arch Neurol 65:1024-1030, Stead,L.G.,et al., 2008
Quality of Life in Patients and Partners After Aneurysmal Subarachnoid Hemorrhage
Stroke 29:798-804, Hopp,J.W.,et al, 1998
Implementation of a Prehospital Stroke Triage System Using Symptom Severity and Teleconsultation in the Stockholm Stroke Triage Study
JAMA Neurol 77:691-699, Mazya, M.V.,et al, 2020
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
NEJM 378:708-718, Albers, G.W.,et al, 2018
Cortical Superficial Siderosis Multifocality in Cerebral Amyloid Angiopathy
Neurol 89:2128-2135, Charidimou, A.,et al, 2017
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
NEJM 372:1009-1018, Campbell, B.C.V.,et al, 2015
Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke
NEJM 372:1019-1030, Goyal, M.,et al, 2015
Interobserver Variability of Grading Scales for Aneurysmal Subarachnoid Hemorrhage
Stroke 42:1546-1549, Degen, L.A.R.,et al, 2011
Intracranial Aneurysms
NEJM 336:28-40, Schievink,W.I., 1997
Utilization of Acute Care Services in the Year Before and After First Stroke:A Population-Based Study
Neurol 46:861-869, 6021996., Leibson,C.L.,et al, 1996
Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994
Management of Aneurysmal Subarachnoid Hemorrhage
Stroke 19:1300-1305, Biller,J.,et al, 1988
Diet Quality is Associated with Disability and Symptom Severity in Multiple Sclerosis
Neurol 90:e1-e11, Fitzgerald, K.C.,et al, 2018
Disability in adults with arthrogryposis is severe, partly invisible, and varies by genotype
Neurol 90:e1596-e1604, Dai, S.,et al, 2018
Neurologic Outcomes in Pediatric Cardiac Arrest Survivors Enrolled in the THAPCA trials
Neurol 91:e123-e131, Ichord, R.,et al, 2018
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
Cortical Lesions in Primary Progressive Multiple Sclerosis: A 2-Year Longitudinal MR Study
Neurol 72:1330-1336, Calabrese,M.,et al, 2009
Longitudinal Follow-Up of "Benign" Multiple Sclerosis at 20 Years
Neurol 68:496-500,480, Sayao,A-L.,et al, 2007
Gray Matter Involvement in Multiple Sclerosis
Neurol 68:634-642, Pirko,I.,et al, 2007
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Comparisons of Patient Self-report, Neurologic Examination, and Functional Impairment in MS
Neurol 56:934-937, Hoogervorst,E.L.J.,et al, 2001
Glatiramer Acetate (Copaxone) Treatment in Relapsing-Remitting MS
Neurol 54:813-817, Ge,Y.,et al, 2000
Relative Contributions of Brain and Cervical Cord Pathology to Multiple Sclerosis Disability: a Study with Magnetisation Transfer Ratio Histogram Analysis
JNNP 69:723-727, Rovaris,M.,et al, 2000
Early Clinical and Radiological Predictors of Fatal Brain Swelling in Ischemic Stroke
Stroke 30:287-292, Krieger,D.W.,et al, 1999
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Benign Multiple Sclerosis? Clinical Course, Long Term Follow Up, and Assessment of Prognostic Factors
JNNP 67:148-152,138, Hawkins,S.A.&McDonnell,G.V., 1999
Assessment of Motor Function After Stereotactic Pallidotomy
Neurol 50:266-270, Ondo,W.G.,et al, 1998
Correlation of Perfusion-and Diffusion-Weighted MRI with NIHSS Score in Acute (<6. 5 hr) Ischemic Stroke
Neurol 50:864-870, 8421998., Tong,D.C.,et al, 1998
Electrical Stimulation of the Subthalamic Nucleus in Advanced Parkinson's Disease
NEJM 339:1105-1111, Limousin,P.,et al, 1998
Paramedian Pontine Infarction
Stroke 28:809-815, Kataoka,S.,et al, 1997
Doctors & Pts Don't Agree:Cross Sectional Study of Pts' & Doctors'Perceptions & Assessments of Disability in MS
BMJ 314:1580-1583, Rothwell,P.M.,et al, 1997
The Impact of Inpatient Rehabilitation on Progressive Multiple Sclerosis
Ann Neurol 42:236-244, Freeman,J.A.,et al, 1997
Ischemic Lesion Volumes in Acute Stroke by Diffusion-Weighted MRI Correlate with Clinical Outcome
Ann Neurol 42:164-170, Lovblad,K-O.,et al, 1997
Prognostic Value of the Hyperdense Middle Cerebral Artery Sign and Stroke Scale Score Before Ultraearly Thrombolytic Therapy
AJNR 17:79-85, Tomsick,T.,et al, 1996
'Malignant'Middle Cerebral Artery Territory Infarction
Arch Neurol 53:309-315, Macke,W.,et al, 1996
Correlation Between Changes in Disability and T2-Weighted Brain MRI Activity in Multiple Sclerosis:A Follow-up Study
Neurol 45:255-260, Filippi,M.,et al, 1995
Decreased SPECT[123I]B-CIT Striatal Uptake Correlates with Symptom Severity in Parkinson's Disease
Ann Neurol 38:589-598, Seibyl,J.P.,et al, 1995
Interrater Agreement in Evaluation of Stroke Patients with the Unified Neurological Stroke Scale
Stroke 25:1263-1264, Treves,T.A.,et al, 1994
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Posttraumatic Headache
Semin Neurol 14:40-45, Packard,R.C., 1994
Measuring Physical Impairment and Disability with the Chedoke-McMaster Stroke Assessment
Stroke 24:58-63, Gowland,C.,et al, 1993
Interferon Beta-1b is Effective in Relapsing-Remitting MS
Clinical Results of a Placebo-Controlled Trial, IFNB MS Study Grp, Neurol 43:655-661, 64193., , 1993
Interferon Beta-1b is Effective in Relapsing Remitting MS, MRI Analysis Results of Placebo-Control Trial
Neurol 43:662-667, 6411993., Paty,D.W.,et al, 1993